The question
At exam pace this item has 1 min 12 s. Commit to an answer before you open the explanation.
Case
A 24-year-old woman with epilepsy attends the neurology clinic to discuss her treatment. She continues to have generalised tonic-clonic seizures despite a full dose of her current medicine, and a change to sodium valproate has been suggested.
PMH: generalised tonic-clonic epilepsy.
DH: levetiracetam 1 g PO twice daily (12-hrly); lamotrigine was stopped last year because of a widespread rash.
SH: sexually active with one partner; uses condoms only. Does not smoke.
On examination: well; BP 118/72 mmHg.
Investigations: a urinary pregnancy test today is negative.
Question
Select the most important information option that should be provided for the patient.
(mark it with a tick)
Information options
- an annual risk acknowledgement form is not needed once she is established on it
- it can be stopped abruptly at any time without risk of further seizures
- it is safe to continue in pregnancy provided high-dose folic acid is taken daily
- it must not be started unless two specialists agree there is no alternative
- it should be taken only when she feels a seizure starting to come on
Show the answer and markingHide the answer
it must not be started unless two specialists agree there is no alternative
Marks2
ExplanationWhen deciding the most important information for this patient, start from the regulatory position rather than from the pharmacology. Following the MHRA Drug Safety Update of January 2024, valproate must not be started in any new patient younger than 55 years — female or male — unless two specialists independently consider and document that there is no other effective or tolerated treatment, or that the reproductive risks do not apply. This patient is 24 and of childbearing potential, so the conversation cannot begin with dosing or with side effects: it has to begin with the fact that starting valproate at all requires that second independent specialist opinion, alongside the pregnancy prevention programme, the annual risk acknowledgement form and highly effective contraception. Valproate exposure in utero carries a risk of major congenital malformation of about 11% and of neurodevelopmental disorder in up to 30–40% of children.
The remaining options are all false. Folic acid does not mitigate the malformation risk of valproate — the MHRA has said so explicitly — and valproate is not safe to continue in pregnancy. The annual risk acknowledgement form is not a one-off: it must be completed with a specialist at initiation and at every annual review for as long as treatment continues. Valproate is prophylactic and is taken regularly; it has no role taken at the onset of a seizure. And no antiepileptic is stopped abruptly — sudden withdrawal precipitates seizures and can precipitate status epilepticus, so any withdrawal is tapered under specialist supervision.
Further information: MHRA/CHM advice, 'Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age', January 2024; NICE NG217, Epilepsies in children, young people and adults.
© 2026 PassthePSA · Question COM-19 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).
How to approach a Communicating Information item
The repeatable method from the Communicating Information section guide.
- Name the worst realistic harmFor this drug in this patient, what is the most serious thing that could go wrong?
- Ask what the patient must do or avoid to prevent itThat action is the candidate answer.
- Check the drug's specific warningsPatient and carer advice, and any important safety information box.
- Rank the remaining optionsSerious and specific beats general and practical.
- Choose oneThe option that, if unsaid, is most likely to end in harm.
Before you submit
- Have I ranked by harm rather than by how often I would say it?
- Is my choice specific to this drug?
- Does it fit this patient's age, pregnancy status and job?
- Is there a regulator warning I have not considered?
- Would the patient know what to do after hearing it?
Practise Communicating Information questions 235 questions, each with a full explanation
More worked examples
- All Communicating Information worked exampleson the section guide
- Worked examples from every sectionthe library in the PSA exam guide
Doses and thresholds in the explanation are as written in the bank on the date given in the explanation. Check them against the current BNF before you rely on them.